Bronchogen
Preclinical ResearchBronchogen (Ala-Glu-Asp-Leu)
A Khavinson bioregulator tetrapeptide targeting bronchial and lung tissue, researched for respiratory function.
Dose
0.1 mg
Route
Subcutaneous injection
Cycle
10-20 days
Storage
2°C to 8°C (refrigerator), protected from light
What is Bronchogen?
Bronchogen, also known by the trade name Chonbrone, is a synthetic tetrapeptide bioregulator developed by the Russian scientist V. Kh. Khavinson. It is classified as a cytomedin, a class of peptides hypothesized to regulate gene expression and protein synthesis in specific tissues. In the case of Bronchogen, its sequence (Ala-Glu-Asp-Leu) is proposed to specifically target cells within the bronchial and lung tissues, potentially modulating their function and promoting cellular homeostasis. Research, primarily from the Khavinson group, suggests its role in respiratory health and lung tissue regeneration. It is supplied as a lyophilized powder for reconstitution and subcutaneous injection in research settings.
Key Benefits
- Bronchial tissue research
🐾 Griffin Says...
Molecular Information
Molecular weight
490.5 g/mol
Type
Tetrapeptide bioregulator
Amino acid sequence
Ala-Glu-Asp-Leu
Bronchogen (Chonbrone) is a synthetic tetrapeptide corresponding to the active site of proteins involved in lung and bronchial tissue regulation, as described by the Khavinson group.
Pharmacokinetics
Time to peak
Information not readily available in public peer-reviewed literature for this specific Khavinson peptide; expected to be relatively rapid (minutes to hours) due to small size.
Half-life
Short — short peptides of this class clear from plasma within minutes; no published human half-life
Time to clear
Information not readily available in public peer-reviewed literature for this specific Khavinson peptide; clearance is expected to be rapid via proteolytic degradation.
Research Indications
Bronchial and Lung Tissue Regulation
Animal studies and in vitro research, primarily from the Khavinson group, suggest Bronchogen's ability to positively influence the functional activity of bronchial and lung cells. Evidence: Animal/in-vitro only.
Support for Respiratory Function
Preclinical data indicates potential for improving parameters related to respiratory function and reducing adverse changes in lung tissue morphology. Evidence: Animal/in-vitro only.
Anti-inflammatory and Antioxidant Effects in Lungs
Some research suggests Bronchogen may contribute to reducing inflammation and oxidative stress within lung tissues. Evidence: Animal/in-vitro only.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Bronchial/Lung Tissue Support in Animal Models | 0.1 mg per animal | Once daily | Subcutaneous |
| Investigation of Lung Tissue Regeneration | 0.05-0.1 mg/kg | Every other day | Subcutaneous |
| Modulation of Respiratory Inflammation | 0.1-0.2 mg per animal | Once daily for 10 days | Subcutaneous |
| In vitro studies on lung cell cultures | 0.1 - 100 ng/mL | Single or repeated application | Cell culture medium |
Optimal timing of administration (e.g., morning vs. evening) for Khavinson peptides is not extensively documented for all applications. Consistency in timing during a research cycle is generally advised.
Peptide Interactions
- Compatible
Other Bioregulators
Khavinson peptides are often studied in combinations with other bioregulators, targeting different organs or systems, with no known negative interactions. However, specific combinations require individual research.
- Monitor Combination
Standard Research Medications
While no direct contraindications are known, researchers should carefully monitor animal subjects when Bronchogen is used concurrently with other pharmacological agents to observe for any unforeseen interactions or altered efficacies.
- Use Caution
Immunosuppressants
Given the potential for bioregulators to modulate cellular processes, caution is advised when co-administering with immunosuppressive agents until specific research on these interactions is available. Potential for altered immune responses.
- Compatible
Oxidative Stress Inducers
Bronchogen has been studied in models involving oxidative stress, and some research suggests it may exert protective effects. This makes it a suitable candidate for co-administration in such research paradigms.
How to Reconstitute
- 1Gather supplies: Bronchogen vial, bacteriostatic water for injection, sterile syringe (e.g., 1mL), sterile needles (e.g., 23-30 gauge for drawing, 29-31 gauge for injecting), alcohol wipes.
- 2Inspect the lyophilized peptide. It should be a dry, white, or off-white powder. If it appears melted or discolored, do not use.
- 3Clean the rubber stopper of both the Bronchogen vial and the bacteriostatic water vial with alcohol wipes. Allow them to air dry.
- 4Using a sterile syringe and needle, draw the desired amount of bacteriostatic water. A common reconstitution ratio is 1mL per 10mg of peptide to achieve a concentration of 10mg/mL (or 0.1mg/10uL for a 1mg vial).
- 5Slowly inject the bacteriostatic water into the Bronchogen vial, aiming the stream against the inside wall of the vial, not directly onto the peptide cake.
- 6Remove the needle and gently swirl the vial between your fingers until the powder is completely dissolved. Do not shake vigorously, as this can damage the peptide.
- 7Once dissolved, the solution should be clear and free of particulate matter. Store the reconstituted solution as directed.
Use a sterile technique for reconstitution. Ensure the bacteriostatic water for injection is slowly added to the vial, allowing it to run down the inside wall to avoid direct impact on the peptide cake. Do not shake the vial; gentle swirling is sufficient until the powder is fully dissolved.
What to Expect
- Initial cycles may be associated with subtle changes, with more noticeable effects potentially emerging after repeated cycles.
- Bronchogen is designed to exert gradual, tissue-specific regulatory effects rather than immediate, dramatic changes.
- Observations in animal studies often include improved respiratory parameters, enhanced lung tissue repair, or reduced inflammatory markers.
- The peptide's mechanism involves interaction with specific DNA sequences, potentially leading to normalization of gene expression in target cells.
- Effects are generally hypothesized to be long-lasting due to epigenetic modulation and cellular memory, supporting cyclic administration rather than continuous use.
Side Effects & Safety
- Bronchogen is a research chemical and is not approved for human consumption. It should only be used for in vitro or animal research purposes.
- Always handle peptides using sterile techniques to prevent contamination, which could compromise research integrity and safety.
- Proper disposal of needles and syringes is crucial. Follow local regulations for biohazardous waste.
- Keep out of reach of children and unauthorized individuals.
- No significant adverse effects have been widely reported in preclinical studies for Bronchogen specifically within typical research dosages. However, as with any research peptide, careful monitoring is warranted.
- Should any unexpected physiological responses occur during animal studies, discontinue administration and consult with a veterinarian or research supervisor.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.